12/17/2007

The combination of tumor drug Avastin with anthracycline-based chemotherapy did not heighten the risk of heart problems in breast cancer patients who underwent surgery, Roche Holding said Saturday. The company intends to finish two late-stage studies on the drug before seeking approval for expanding its use to different types of tumors and different stages of breast cancer.

Full Story:
Bloomberg1

Related Summaries